Linden Thomas Advisory Services’s DexCom DXCM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$5.96M Sell
69,017
-65
-0.1% -$5.41K 0.47% 35
2026
Q2
$4.65M Buy
69,082
+23,616
+52% +$1.57M 0.38% 60
2026
Q1
$2.86M Buy
45,466
+17,777
+64% +$1.24M 0.28% 108
2025
Q4
$1.84M Sell
27,689
-1,417
-5% -$91.6K 0.19% 170
2025
Q3
$1.96M Buy
29,106
+1,068
+4% +$84.5K 0.2% 153
2025
Q2
$2.45M Buy
28,038
+4,455
+19% +$349K 0.27% 108
2025
Q1
$1.61M Buy
23,583
+1,811
+8% +$148K 0.21% 179
2024
Q4
$1.69M Buy
21,772
+473
+2% +$35K 0.21% 166
2024
Q3
$1.43M Buy
21,299
+1,205
+6% +$99K 0.2% 206
2024
Q2
$2.28M Buy
20,094
+5,844
+41% +$739K 0.35% 66
2024
Q1
$1.98M Buy
14,250
+874
+7% +$110K 0.32% 97
2023
Q4
$1.66M Buy
13,376
+330
+3% +$33.7K 0.31% 114
2023
Q3
$1.22M Sell
13,046
-3,643
-22% -$411K 0.27% 168
2023
Q2
$2.14M Buy
16,689
+202
+1% +$24.4K 0.48% 39
2023
Q1
$1.92M Buy
16,487
+566
+4% +$63.4K 0.48% 46
2022
Q4
$1.8M Buy
+15,921
New +$1.75M 0.51% 46

Other funds holding DXCM

Linden Thomas Advisory Services's DXCM Position: Q3 2026 in Review

Linden Thomas Advisory Services reduced its DexCom (DXCM) stake by 0.09% in Q3 2026, selling an estimated $5.41K and leaving 69,017 shares worth $5.96M. The position accounts for 0.47% of the portfolio, ranked #35.

Linden Thomas Advisory Services first reported a position in DXCM in Q4 2022 and has held it in 16 quarters since. 482 funds tracked by Wall St. Rank hold DXCM as of Q3 2026.

  • Linden Thomas Advisory Services held 69,017 shares of DexCom worth $5.96M as of Q3 2026.
  • Linden Thomas Advisory Services sold 65 DexCom shares in Q3 2026, an estimated $5.41K.
  • DexCom made up 0.47% of Linden Thomas Advisory Services's portfolio in Q3 2026, its #35 holding.
  • Linden Thomas Advisory Services first reported a position in DexCom in Q4 2022 and has held it in 16 quarters since.
  • 482 funds tracked by Wall St. Rank held DexCom as of Q3 2026.

Based on Linden Thomas Advisory Services's 13F filing for Q3 2026, filed 19 Oct 2026.